Navigation Links
CardioDynamics BioZ(R) ICG Technology Integrates with General Electric Healthcare's Centricity(R) Electronic Medical Record (EMR) System
Date:8/5/2008

GE Centricity(R) -- Third Largest U.S. Outpatient EMR with Nearly 10%

Market Share

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) impedance cardiography (ICG) technology, today announced that the Company's BioZ(R) Dx now seamlessly integrates with General Electric Healthcare's Centricity(R) electronic medical record (EMR) system.

The Company released this week its latest version of BioZport(R) ICG data management software which includes capabilities to automatically integrate and transfer BioZ(R) ICG data from the BioZ(R) Dx to GE Healthcare's Centricity(R) EMR system. This is a strategic advancement for the Company's flagship product as EMR interface and paperless workflow are increasingly becoming necessities to the outpatient physician when making decisions on new medical technologies. Currently, it is estimated that 24% of U.S. outpatient physicians utilize an EMR system. Medical device to EMR interface capability will continue to grow in importance as U.S. outpatient-based physician use of EMR is forecasted to grow at over 16% per year through 2013.

Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "We are extremely pleased to release our initial BioZ ICG direct EMR interface. EMR is a driving, essential factor in the majority of medical device decisions for early adopter physicians and large physician practices. Interfacing with our long-time partner, GE Healthcare, whose Centricity(R) system has nearly 10% share in our sizable outpatient physician market, is a great accomplishment for our company, customers, prospective customers and investors."

Perry continued, "Our EMR strategy is to partner with the top 10% to 15% of EMR suppliers, who collectively have 80% of U.S. outpatient market share. Allscripts, the second largest outpatient EMR provider, with over 12% market share, is our next planned interface. With increasing penetration rates for both ICG and EMR, interface capability should further accelerate the adoption of ICG and supports our long-term vision that BioZ ICG is present in every physician office that prescribes cardiovascular medicine for heart failure, shortness of breath and high blood pressure patients."

BioZ ICG technology presently resides in approximately one out of every six (16%) cardiology offices as well as one out of every five (20%) outpatient heart failure clinics in the United States with over one million BioZ tests performed annually.

For further information, please contact Emma Brejwo at ebrejwo@cdic.com.

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called BioZ(R) Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive BioZ(R) ICG products and medical device electrodes. The Company's BioZ(R) ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems, and Mindray. For additional information, please refer to the company's Web site at http://www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is necessarily subject to uncertainties and risks including the Company's sole dependence on the BioZ(R) product line, and various uncertainties characteristic of early growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2007 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.


'/>"/>
SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
2. CardioDynamics Receives Nasdaq Letter of Non-Compliance With Minimum Bid Price Requirement
3. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
4. CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego
5. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
6. CardioDynamics Provides 2007 Shareholder Meeting Update
7. New Book on the Business of Biotechnology
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. eResearchTechnology Reports Second Quarter 2008 Results
10. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
11. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):